Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Active, not recruiting · NCT04300244 · Registry updated 2024-02-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, cancer, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2024-02-29 | NCT04300244 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Oslo University Hospital | 327 |
| Ultimovacs ASA | 1 |
| Åslaug Helland | 1 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aalborg University Hospital | Aalborg | Denmark | 32 |
| Copenhagen University Hospital | Copenhagen | Denmark | 3 |
| Karolinska | Stockholm | Sweden | 2 |
| Oslo University Hospital | Oslo | Norway | 111 |
| University Hospital of Skåne | Lund | Sweden | 1 |
| University of Western Australia | Perth | Australia | 2 |
| Vall d'Hebron Institute of Oncology | Barcelona | Spain | 8 |